Salarius Pharmaceuticals Announces MD Anderson Cancer Center Presents Clinical Data On Seclidemstat For MDS And CMML At 2024 European Hematology Association Congress
Portfolio Pulse from Benzinga Newsdesk
Salarius Pharmaceuticals announced that MD Anderson Cancer Center presented clinical data on seclidemstat for MDS and CMML at the 2024 European Hematology Association Congress. The Phase 1/2 study showed a 43% overall response rate among 14 patients, with a median overall survival of 18.5 months and median event-free survival of 7.2 months.
June 17, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Salarius Pharmaceuticals' seclidemstat demonstrated a 43% overall response rate in a Phase 1/2 study for MDS and CMML, with promising survival metrics. This positive clinical data could boost investor confidence and potentially drive the stock price up in the short term.
The positive clinical data presented at a major conference is likely to increase investor confidence in Salarius Pharmaceuticals. The 43% response rate and favorable survival metrics are significant for a company in the biotech sector, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100